Pharma group calls for broader U. S. market approach in Medicare
WASHINGTON (Reuters) – The role of the U. S. pharmaceutical industry within Medicare should be expanded as a way to reduce the popular healthcare program’s contribution to the federal deficit without resorting to drug rebates, the chief of the industry’s trade group said on Thursday. John Castellani, head of the Pharmaceutical Research and Manufacturers of America, or PhRMA, proposed applying elements of the Medicare Part D prescription drug program to other areas including drug benefits under Medicare Part B, which covers visits to doctor’s offices and outpatient clinics. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply